Wednesday, November 02, 2005

Selecting siRNA Sequences to Incorporate into the pSilencer Vectors
The first step in preparing a plasmid for siRNA
experiments is to identify target sequences in the gene of interest
that are susceptible to siRNA-induced degradation. We have found
that a little more than half of the siRNAs provide at least a 50%
reduction in target mRNA levels and approximately 1 out of 4 siRNAs
provide a 75-95% reduction. The general process begins with scanning
the length of the target gene for potential siRNA target sites. For
siRNA expression vectors, the target sites should have 5' terminal
AAs because, upon folding the siRNAs hairpins will give rise to UU
overhangs. These UU overhangs will therefore be complementary to the
AA in the target site. The 21 nucleotide siRNA target sequences are
then compared to an appropriate genome database to eliminate
sequences with significant homology to other genes. For screening,
we typically test four siRNAs per target. We space the siRNAs down
the length of the gene sequence to reduce the chances of targeting a
region of the mRNA that is either highly structured or bound by
regulatory proteins.
Constructing four siRNA expression plasmids for each target
can be time-consuming and expensive. In vitro transcription provides a
less formidable siRNA screening method. To ensure that siRNAs expressed
from plasmids are functionally equivalent to siRNAs prepared by in vitro
transcription, we prepared plasmids and siRNAs targeting four different
sequences in the cyclophilin and GAPDH genes. These nucleic acids were
transfected into HeLa cells. Silencing was evaluated by Northern analysis
using probes specific to GAPDH, cyclophilin, and 28S rRNA. The hybridization
signal from the various targets was quantitated by phosphorimager. As
seen in Figure 1, the susceptibility of siRNA target sites to siRNA-mediated
gene silencing appears to be comparable for both in vitro prepared siRNAs
and RNA Pol III-expressed siRNAs. This is also true for chemically synthesized
siRNAs versus RNA Pol III-expressed siRNAs. Therefore, it is not necessary
to re-screen genes for which functional siRNAs have already been identified.
Transcribed siRNA
siRNAVector
GAPDH
None
100%
100%
5'
25%
17%
5' Medial
7%
13%
3' Medial
36%
20%
3'
45%
63%
Cyclophilin
None
100%
100%
5'
5%
23%
5' Medial
15%
19%
3' Medial
45%
29%
3'
70%
54%
Figure 1. Correlation of Target Site Selection Between
siRNA Generated In Vitro and In Vivo. siRNAs to four target sites in each of two
genes (GAPDH and cyclophilin) were selected and prepared using the Silencer™
siRNA Construction Kit. Sequences encoding hairpin siRNAs to the same
target sequences were sub-cloned into pSilencer 2.0-U6 and 3.0-H1.
The siRNAs and siRNA expression vectors were transfected into HeLa cells
using siPORT™-Lipid
(Ambion). Target RNA levels were assessed post-transfection (48 hr) by
Northern analysis using the NorthernMax™
procedure (Ambion). The relative levels of the target genes were measured
against cells transfected with negative control siRNA or negative control
siRNA expression vector.
back to top
Ordering Information
Cat#
Product Name
Size
1620
Silencer® siRNA Construction
Kit
15 siRNA synthesis rxns
7207
pSilencer™ 1.0-U6 (circular)
20 µg
7208
pSilencer™ 1.0-U6 (linear)
20 rxns
7209
pSilencer™ 2.0-U6
20 rxns
7210
pSilencer™ 3.0-H1
20 rxns